← Back to Peptide Library

Triptorelin

Mixed evidence
Sexual health

A long-acting prostate-cancer drug that some communities reinvented as a single-shot hormone restart, resting on a thin anecdote.

What it is

Triptorelin is a modified, long-lasting version of GnRH, the brain hormone that runs reproduction. A chemical tweak makes it survive in the body much longer than the natural hormone, turning minutes into hours. It is an FDA-approved drug for advanced prostate cancer and for a form of early puberty.

How it works

It works in two phases. First it strongly signals the pituitary, causing a flare of LH and FSH. Then, with continued use, the receptor dulls to its signal and sex-hormone production crashes to castrate levels, which is what oncologists want. The community use targets the opposite: the brief flare window, hoping to restart natural testosterone after a cycle.

What people report

  • Resoundingly effective for its approved uses: suppressing testosterone in prostate cancer and managing central precocious puberty
  • A single shot could in theory prompt a hormonal restart, which is why the idea appeals
  • Long-acting depot versions cover 1, 3, and 6-month dosing for medical use
  • Approved for endometriosis and fibroids in some regions

Typical use

In medicine it is given as a depot injection every 1–6 months for continuous suppression. The community 'restart' idea centers on the flare in the first 48–72 hours after a single dose, before suppression kicks in.

Dosing reference

The solo-restart story traces to one case report: a single 34-year-old man, one 100 mcg test dose, recovery over a month. That is a narrow anecdote, not a protocol library. Verify any dosing against the fact that the window is far narrower than forums imply.

Reference only — not a recommendation. Verify via primary sources.

Watch for

Used wrong, the suppression phase becomes the outcome, not the recovery. The risk is real: a single misjudged shot can shut down, not restart, your axis. HCG plus a SERM remains the better-characterized historical approach, and WADA bans GnRH agonists for male athletes at all times.

Educational content — not medical advice.